实体肿瘤病史对弥漫大B细胞淋巴瘤治疗反应及生存的影响
该回顾性研究纳入836例DLBCL患者,其中34例有实体肿瘤病史为双癌组,按1∶2倾向评分匹配68例无实体瘤病史者为对照组。双癌组与对照组RCHOP后完全缓解率分别为79.4%和67.6%(P=0.210),3年OS率分别为(74.7±9.5)%和(63.5±6.1)%(P=0.095),3年PFS率分别为(72.1±8.8)%和(54.3±6.4)%(P=0.237),均无统计学差异。结论认为实体瘤病史不影响DLBCL患者治疗反应及近期生存。
要点
- 双癌组与对照组RCHOP后完全缓解率分别为79.4%与67.6%,差异无统计学意义(P=0.210)。
- 双癌组与对照组3年OS率分别为(74.7±9.5)%与(63.5±6.1)%,差异无统计学意义(P=0.095)。
- 双癌组与对照组3年PFS率分别为(72.1±8.8)%与(54.3±6.4)%,差异无统计学意义(P=0.237)。
核心结论
- 实体肿瘤病史不影响DLBCL患者的治疗反应及近期生存。
研究设计与样本
- 回顾性研究纳入2013—2018年瑞金医院血液科治疗的DLBCL患者836例,其中34例有实体肿瘤病史者为双癌组。
- 从802例无实体肿瘤病史者中按1∶2倾向评分匹配(匹配因素含年龄、性别、IPI评分等)选出68例为对照组。
主要发现
- 双癌组与对照组RCHOP后完全缓解率分别为79.4%与67.6%(P=0.210)。
- 双癌组与对照组3年OS率分别为(74.7±9.5)%与(63.5±6.1)%(χ²=2.791,P=0.095)。
- 双癌组与对照组3年PFS率分别为(72.1±8.8)%与(54.3±6.4)%(χ²=1.400,P=0.237)。
- 102例中双癌组死亡6例、对照组死亡24例,两组中位生存时间均未达到。
临床怎么用
- 对合并实体肿瘤病史的DLBCL患者,RCHOP方案治疗反应及近期生存与无实体瘤病史者无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe whether the history of solid tumors affects the treatment response and survival situation of patients with diffuse large B-cell lymphoma (DLBCL) . Methods: A retrospective study was conducted in 836 patients with DLBCL who were treated in the Department of Hematology at Ruijin Hospital from 2013 to 2018. Among them, 34 DLBCL patients who had the history of solid tumors were classified into double cancer group. From 802 patients without history of solid tumors, 68 DLBCL patients were selected as control group, using 1∶2 matching on propensity scores for age, gender, IPI score and etc. All patients included in the study had follow-up interviews through medical record and telephone for mortality from any cause. Treatment response and 3-year overall survival (OS) and progression-free survival (PFS) of two groups were analyzed. Results: The complete remission rates after RCHOP (Rituximab+Cyclophosphamide+Vincristine+Adriamycin 50 mg/m(2) or Epirubicin or Liposome Adriamycin+Prednisone) regimen were 79.4% and 67.6% in the double cancer group and the control group, respectively (P=0.210) . Among the 102 patients, 6 patients died in the double cancer group while 24 patients died in the control group and the median survival time of both two groups were not reached. The 3-year OS were (74.7±9.5) % and (63.5±6.1) % (χ(2)=2.791, P=0.095) , while 3-year PFS were (72.1±8.8) % and (54.3±6.4) % (χ(2)=1.400, P=0.237) in the double cancer group and the control group, respectively. Conclusion: The history of solid tumors didn't affect DLBCL patients' treatment response and short-term survival. 目的: 观察合并实体肿瘤病史是否会影响弥漫大B细胞淋巴瘤(DLBCL)患者的治疗效果以及生存情况。 方法: 回顾性收集2013-2018年在上海交通大学医学院附属瑞金医院血液科治疗的DLBCL患者836例,其中34例有实体肿瘤病史的DLBCL患者归为双癌组,从802例无实体肿瘤病史的DLBCL患者中,应用倾向评分匹配方法,根据性别、年龄、分期、IPI评分等因素进行1∶2匹配,筛选出68例作为对照组。通过门诊、住院资料及电话随访,比较两组患者的治疗缓解率、3年总生存(OS)及无进展生存(PFS)期的差异。 结果: 双癌组和对照组RCHOP(利妥昔单抗+环磷酰胺+长春新碱+阿霉素50 mg/m(2)或表阿霉素或脂质体阿霉素+泼尼松)治疗完全缓解率分别为79.4%及67.6%,差异无统计学意义(P=0.210);3年OS率分别为(74.7±9.5)%及(63.5±6.1)%(χ(2)=2.791,P=0.095),差异无统计学意义;3年PFS率分别为(72.1±8.8)%及(54.3±6.4)%(χ(2)=1.400,P=0.237),差异亦无统计学意义。 结论: DLBCL合并实体瘤病史不影响患者近期生存及RCHOP方案疗效。.
引用
- Meng YN, Shi Q, Cheng S, et al. [Impact of solid tumor history on treatment response and survival of patients with diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495129. doi:10.3760/cma.j.issn.0253-2727.2019.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。